gtbp_corresp
GT
BIOPHARMA, INC.
9350
Wilshire Blvd.
Suite
203
Beverly
Hills, CA 90212
April
23, 2021
Via
EDGAR Submission
United
States Securities and Exchange Commission
Division of
Corporation Finance
Office
of Life Sciences
100 F
Street, N.E.
Washington, D.C.
20549
Attention: Chris Edwards
Registration
Statement on Form S-1
CIK No.
0000109657
SEC
Registration No. 333-255429
Ladies
and Gentlemen:
In
accordance with Rule 461 of Regulation C of the General Rules and
Regulations under the Securities Act of 1933, as amended, we hereby
request acceleration of the effective date of the Registration
Statement on Form S-1 (File No. 333-255429) (the
“Registration
Statement”) of GT Biopharma, Inc. (the
“Company”). We
respectfully request that the Registration Statement become
effective as of 5:00 p.m., Eastern Time, on April 27, 2021, or as
soon as practicable thereafter. Once the Registration Statement has
been declared effective, please orally confirm that event with our
counsel, Baker & McKenzie LLP by calling Roger Bivans at (214)
978-3095.
Thank
you for your assistance with this matter.
Michael
Handelman
Chief
Financial Officer
Click here to enter Sender1 Email Address.
|
|